Catalog No.
KAV13302
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant MPXV M1R has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Human Anti-Monkeypox Virus IgG (M1R) present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Human Anti-Monkeypox Virus IgG (M1R) bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
M1R
Applications
Used for the quantitative determination of Human Anti-Monkeypox Virus IgG (M1R) concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31 - 20 ng/mL
Sensitivity
0.26 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
8.4
|
1.5
|
0.4
|
8.9
|
2.3
|
0.6
|
|
Standard deviation
|
0.6
|
0.1
|
0.0
|
0.8
|
0.2
|
0.1
|
|
CV (%)
|
6.8
|
5.5
|
3.6
|
8.7
|
7.5
|
8.5
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20 ℃, the rest reagents should be store at 4℃.
A Single-Chain Mpox mRNA Vaccine Elicits Protective Immune Response in Mice., PMID:40432124
A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370
Current status of next-generation vaccines against mpox virus: a scoping review., PMID:40356988
Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox., PMID:40239465
Generation and characterization of neutralizing antibodies against M1R and B6R proteins of monkeypox virus., PMID:40164599
Identification of neutralizing nanobodies protecting against poxvirus infection., PMID:40133273
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
Immunoinformatics approach: Developing a multi-epitope vaccine with novel carriers targeting monkeypox virus., PMID:39679938
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Computational identification of monkeypox virus epitopes to generate a novel vaccine antigen against Mpox., PMID:39471737
Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus., PMID:39321566
Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus., PMID:39233480
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
Cross-reactive antibody response to Monkeypox virus surface proteins in a small proportion of individuals with and without Chinese smallpox vaccination history., PMID:37784185
A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice., PMID:37766097
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge., PMID:37739969
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Recombinant proteins A29L, M1R, A35R, and B6R vaccination protects mice from mpox virus challenge., PMID:37435062
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review., PMID:37353117
Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus., PMID:37117161
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge., PMID:26086739
For research use only. Not for human or drug use.
